• Vorinostat Workflows for Epigenetic Oncology

  2026-09-08

  Build reproducible Vorinostat experiments that connect HDAC inhibition with chromatin remodeling, proliferation loss, and mitochondrial apoptosis. This workflow also shows how the AMC-Hem HO-1 activity platform can serve as a carefully bounded orthogonal assay rather than an assumed mechanism.

• Plk1 Control of p31comet in Checkpoint Disassembly

  2026-09-07

  The reference study identifies Polo-like kinase 1 as a negative regulator of p31comet-mediated mitotic checkpoint complex disassembly. Its biochemical and cell-extract experiments show that Plk1 phosphorylates p31comet at S102, reducing cooperation with TRIP13 and providing a mechanism to prevent premature checkpoint silencing.

• Ampicillin Sodium in Protein and Cell Assays

  2026-09-07

  Ampicillin sodium is more than a selection antibiotic: it is a useful experimental boundary condition in antibacterial assays and recombinant protein workflows. This article connects transpeptidase inhibition with the annexin V purification strategy reported in a foundational biophysical study.

• CGP 55845 hydrochloride for Synaptic Assays

  2026-09-05

  Use CGP 55845 hydrochloride as a selective pharmacological switch for separating GABAB-dependent signaling from astrocytic GAT-3 mechanisms in controlled in vitro experiments. Its strongest value is comparative: it links receptor antagonism, neurotransmitter release modulation, and dentate gyrus synaptic physiology without implying that it directly inhibits GAT-3.

• Linezolid: An Assay-First Guide to Resistance Biology

  2026-09-05

  Linezolid is an oxazolidinone antimicrobial whose ribosome-directed activity makes it a valuable reference compound for resistant Gram-positive pathogen research. This guide builds an evidence ladder from biochemical mechanism to whole-cell phenotypes and contrasts it with MmpL3-focused tuberculosis discovery.

• Cefazedone (Refosporen): Applied Research Workflows

  2026-09-04

  Cefazedone (Refosporen) supports practical susceptibility testing, β-lactamase-focused experiments, and translational pharmacokinetic workflows. This guide connects broth dilution design with a validated UFLC–MS/MS method for measuring cefazedone alongside etimicin in plasma.

• circHIF1A Axis Drives M2 Polarization in LUAD

  2026-09-04

  The reference study identifies a circHIF1A/miR-486-5p/GRHL2 competing endogenous RNA axis that links malignant lung adenocarcinoma behavior with macrophage M2 polarization. Patient samples, LUAD cell models, and xenografts indicate that this pathway promotes tumor growth while remodeling the immune microenvironment through IL-10-associated signaling.

• TCAIM–OGDH Control of Mitochondrial Metabolism

  2026-09-03

  A 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. This work establishes mitochondrial proteostasis as a post-translational regulator of OGDH complex activity, carbohydrate catabolism, and broader metabolic state.

• ONX-0914: Reading Immunoproteasome Biology

  2026-09-02

  ONX-0914 and PR-957 provide a selective way to interrogate LMP7-dependent immune signaling. This article connects cytokine production blockade and autoimmune models with a seminal study showing how immunoproteasome activity can reshape antiviral restriction and experimental design.

• Spatial Lipid Changes in Postoperative Cognitive Dysfunction

  2026-09-02

  This 2024 study combines spatial metabolomics, behavioral testing, immunofluorescence, and electron microscopy to identify hippocampal lipid remodeling associated with postoperative cognitive dysfunction after cardiopulmonary bypass. Its intervention data implicate reduced iPLA2 activity and increased serine palmitoyltransferase signaling as potentially modifiable features, while highlighting the value of region-resolved lipid analysis in neurocognitive research.

• Persistent rDNA Damage and PML-Nucleolar Compartments

  2026-09-01

  Urbancokova, Hornofova, and colleagues show that topological stress and RNA polymerase I inhibition generate persistent lesions in ribosomal DNA that drive PML-nucleolar associations. By combining genotoxic-stress screening with targeted I-PpoI cleavage and repair-pathway perturbation, the study links unresolved rDNA damage to nucleolar reorganization and cellular senescence.

• CCK-8 for Translational Cancer Research

  2026-09-01

  Discover how Cell Counting Kit-8 (CCK-8) can connect metabolic viability measurements with translational cancer research. This article presents a rigorous framework for interpreting WST-8 data in antibody-drug conjugate and immunotherapy studies, while clarifying assay limits and experimental design choices.

• Protease Inhibitor Cocktail for Plant Signaling

  2026-08-31

  Discover how a Protease Inhibitor Cocktail can preserve transient plant signaling proteins and phosphorylation states during symbiosis research. This workflow-centered guide connects plant cell protein stability with assay design, using the NSP2–MYB40 discovery as a practical case study.

• Spirocyclic POM Analogues Target MmpL3 in TB

  2026-08-31

  The reference study develops spirocyclic phenyl oxazole methyl analogues and identifies compound 5c as a potent inhibitor of Mycobacterium tuberculosis, including drug-resistant clinical isolates. Genetic resistance analysis, molecular docking, ADME and pharmacokinetic profiling, and THP-1 cytotoxicity testing support MmpL3 as a mechanistic target and establish a useful starting point for anti-tubercular drug discovery.

• STING Agonist-1 and B Cell Immunity

  2026-08-30

  A translational framework for using STING agonist-1 to investigate the relationship between innate immune signaling, CD40–TRAF2 biology, IRF4-driven B cell activation, and tertiary lymphoid structures in cancer research.

8072 records 1/539 page Next 12345 下5页 Last page